Therapies to treat infectious diseases are very scarce. With the emergence of new viruses and variants that threaten human health, the development of antiviral therapies is a pressing and imminent step towards the control of current and future epidemics.
Rumi Viro’s technology is a powerful engine for the discovery of antiviral therapeutics. It offers unprecedented access to human tissues to understand how viruses cause diseases and epidemics. Rumi Viro is uniquely positioned to discover treatments for viral infectious diseases with its cutting-edge science.
Drug development is a lengthy, expensive process with unpredictable outcomes. Diseases caused by emerging viruses are an enormous global health and economic burden as they affect millions of people every year, often due to lack of effective treatments.
CASE STUDY: The emergence of a new human coronavirus, SARS-CoV-2, in late 2019 has sparked an explosive global pandemic of COVID-19 disease, with millions of infections and deaths. Due to a lack of antiviral therapies targeting SARS-CoV-2, the socioeconomic impact of the COVID-19 pandemic has been profound, with the mobility and productivity of a large fraction of the world’s population dramatically curtailed. As with COVID-19, a solution is needed for a timely identification and development of antiviral drugs to prevent outbreaks and epidemics caused by emerging viruses of concern.
Rumi Viro was formed with the goal of speeding up the development of revolutionary treatments for viral infectious diseases, while aiming to develop effective treatments for these diseases. Rumi Viro is creating innovative paradigms of drug development and new treatments for infectious diseases that greatly reduce the impact of viruses on human health. Rumi Viro’s technologies provide an expedited path for creating faster, more effective screening, development, and implementation to treat infectious diseases.